EATONTOWN, N.J., June 2 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Amex: RPC) today announced that Ronald M. Nordmann has joined the Company's
Board of Directors. Roberts said that with today's announcement, its Board of
Directors consists of nine members with Mr. Nordmann joining as the seventh
outside director.
"Ron possesses a wealth of pharmaceutical experience that spans both the
industry and the financial community," said John T. Spitznagel, Roberts'
President and CEO. Since 1994, Mr. Nordmann has been a Partner and Portfolio
Manager with Deerfield Management, a large health care investment fund.
Additional wall street experience includes: Managing Director, Senior
Healthcare Analyst with PaineWebber Inc. and Senior Vice President, Senior
Healthcare Analyst with Oppenheimer & Co.
Prior to joining the financial community, Mr. Nordmann served as Manager,
Marketing Research for the Warner-Lambert Co. (Warner-Chilcott Laboratories)
where he headed a research team engaged in market studies, therapeutic
category analyses, long-range planning, and customized projects. He received
a BA degree in Business and Industrial Management from Johns Hopkins
University and a MBA degree, Magna Cum Laude, from Fairleigh Dickinson
University.
"Ron is an eminently qualified professional with an outstanding career in
pharmaceutical analyses and marketing," said Mr. Spitznagel. "His election to
our Board reflects Roberts' continued commitment to the growth of our
operations and to the enhancement of shareholder value," noted Mr. Spitznagel.
Robert A. Vukovich, Ph.D., Chairman of Roberts' Board of Directors said,
"We are fortunate to have Ron join our Board. His background and proven
talents complement the strengths of our distinguished board members and we
look forward to his input and guidance."
Mr. Nordmann was elected to the Roberts' Board at the annual meeting of
shareholders held on May 27, 1999. At that meeting, shareholders also
re-elected the Honorable Marilyn Lloyd and Messrs. Digby Barrios, Zola
Horovitz, Joseph Noonburg, Joseph Smith, and Robert Vukovich as outside
Directors. Mr. John Spitznagel, Roberts' President and CEO, and Mr. Robert
Loy, Executive Vice President of Operations, were also re-elected to the
Board.
Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada and the United Kingdom, focuses on value-added specialty
pharmaceuticals in the therapeutic categories of gastroenterology, urology,
oncology/hematology, and cardiology/neurology. Roberts actively pursues its
strategy of Search & Develop to identify and acquire novel post-discovery drug
candidates to advance through late-stage clinical development while also
pursuing opportunities to acquire and enhance the potential of commercially
available specialty medicines.
This and past press releases of Roberts Pharmaceutical Corporation are
available through the Internet at the Roberts' home page at
http://www.robertspharm.com.
This release contains forward looking statements which are based on
assumptions and external factors, including assumptions relating to, but not
limited to regulatory action, product pricing, competitive market conditions,
unaudited financial data, new product development and other risks or
uncertainties detailed from time to time in Roberts filings with the
Securities and Exchange Commission. These forward-looking statements
represent the Company's judgment as of the date of this release and any
changes in the assumptions or external factors could produce significantly
different results.
SOURCE Roberts Pharmaceutical Corporation
 back to top
Related links:
http://www.robertspharm.com
CONTACT:
Media - Stuart Z. Levine, Ph.D., V.P.
Corporate Communications, Roberts Pharmaceutical Corporation,
732-676-1200, ext. 3064
|
